<![CDATA[<body bgcolor="#FFFFFF" text="#000000">
In a span of 4 years, the research division has yielded dramatic results, thereby justifying the relatively high initial investments. The company has made considerable progress in developing a drug targeting the asthma/COPD segment, drugs for other inflammatory conditions and a drug for Type II diabetes.
The projects that Glenmark is currently focusing on are in the following areas:
Therapeutic Area
Target
Status
Asthma/COPD
PDE-4
GRC 3886 has completed Preclinical tests and Phase I
Results of Phase I have shown it to be a non-emetic, safe, bio-available compound with a long half-life in healthy human volunteers.
The high level of inhibition of TNF-Alpha, a biomarker associated with inflammation, indicates high probability of efficacy in humans (this will be tested in Phase II)
Development partner for North America, Forest Labs, to commence Phase II by beginning calendar 2006
Development partner for Japan is Teijin Pharmaceuticals Ltd, a part of the $ 8.3 Bn Teijin group
Diabetes DPP-IV
GRC 8200 in preclinical testing
Long acting drug; promising results
Could be filed for Phase I in Q1-Q2 FY2006
CNS [Alzheimer's, Cognitive Disorders, etc.] PDE4
In preclinical testing
One lead expected to enter Phase I by end FY 2006
Other Inflammatory indications such as IBD, Atopic Dermatitis PDE4
</body>]]>